Bile acid conjugated chitosan oligosaccharide nanoparticles for paclitaxel carrier

Park, Jun-Kyu; Nam, Joung-Pyo; Park, Seong-Cheol; Park, YungHoon; Jang, Mi-Kyeong; Nah, Jae‐Woon

doi:10.1007/s13233-014-2034-9

Cited by 8 publications

(6 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cholic acid conjugated chitosan nanoparticles were demonstrated as the drug carriers for paclitaxel. The paclitaxel-loaded nanoparticles showed remarkably high anticancer activity compared to that of paclitaxel in Cremophor EL-ethanol formulation against B16F10 cells [ 16 ]. Carbohydrate-bearing chitosans were also found to be promising liver-targeted [ 17 , 18 ] nanocarriers for hepatic drug targeted delivery [ 19 , 20 , 21 , 22 ].…”

Section: Introductionmentioning

confidence: 99%

Design and Synthesis of Lactose, Galactose and Cholic Acid Related Dual Conjugated Chitosan Derivatives as Potential Anti Liver Cancer Drug Carriers

Ding

Cui

Prasad³

et al. 2021

Polymers

View full text Add to dashboard Cite

Cholic acid and galactose or lactose dual conjugated chitosan derivatives were designed and synthesized as potential anti liver cancer drug carriers, their structures were characterized through proton NMR spectra, elemental analysis, size distribution, zeta potential, and scanning electron microscope image studies. The ability of the dual conjugates to enhance the aqueous solubility of the cancer drug sorafenib was evaluated. The entrapment efficiency (EE%) and drug content (DC%) of sorafenib in the inclusion complexes were measured. The chitosan dual conjugate with cholic acid and galactose was found to be best in enhancing the aqueous solubility of sorafenib. The solubility of sorafenib in water has increased from 1.7 µg/mL to 1900 µg/mL which is equal to 1117-fold increase in its solubility due to the inclusion complex with chitosan conjugate.

show abstract

Section: Introductionmentioning

confidence: 99%

Design and Synthesis of Lactose, Galactose and Cholic Acid Related Dual Conjugated Chitosan Derivatives as Potential Anti Liver Cancer Drug Carriers

Ding

Cui

Prasad³

et al. 2021

Polymers

View full text Add to dashboard Cite

show abstract

“…These NPs are formed by covalent attachment of deoxycholic acid to CS. The self-aggregated NPs have been used as a carrier for drugs, such as Adriamycin,23 paclitaxel,24 doxorubicin,25 DNA12 and gene 26. The NPs prepared by self-assembly of the amphiphilic polymer in aqueous solution can encapsulate hydrophobic drugs into its hydrophobic core, leaving its hydrophilic parts on the surface.…”

Section: Introductionmentioning

confidence: 99%

<p>Ocular anti-inflammatory activity of prednisolone acetate loaded chitosan-deoxycholate self-assembled nanoparticles</p>

Hanafy¹,

Abdalla²,

Guda³

et al. 2019

IJN

View full text Add to dashboard Cite

Background and purpose: Conventional topical ophthalmic aqueous solutions and suspensions are often associated with low bioavailability and high administration frequency, pulsatile dose and poor exposure to certain ocular parts. The aim of this study was to develop an ophthalmic nanoparticles loaded gel, for delivering prednisolone acetate (PA), to increase dosing accuracy, bioavailability, and accordingly, efficiency of PA in treating inflammatory ocular diseases. Methods: A novel formulation of self-assembled nanoparticles was prepared by the complexation of chitosan (CS) and, the counter-ion, sodium deoxycholate (SD), loaded with the poorly-water-soluble PA. Particle size, zeta potential, encapsulation efficiency (EE) and drug loading content (LC) of prepared nanoparticles were assessed. Moreover, the nanoparticles were characterized using differential scanning calorimetry (DSC) and Fourier transform infrared spectroscopy (FTIR). Drug release and eye anti-inflammatory potential of the prepared novel formulation was investigated. Results: Mean particle size of the nanoparticles have dropped from 976 nm ±43 (PDI 1.285) to 480 nm ±28 (PDI 1.396) when the ratio of CS-SD was decreased. The incorporation of 0.1-0.3% of polyvinyl alcohol (PVA), in the preparation stages, resulted in smaller nanoparticles: 462 nm ±19 (PDI 0.942) and 321 nm ±22 (PDI 0.454) respectively. DSC and FTIR results demonstrated the interaction between CS and SD, however, no interactions were detected between PA and CS or SD. Drug release of PA as received, in simulated tears fluid (pH 7.4), showed a twofold increase (reaching an average of 98.6% in 24 hours) when incorporated into an optimized nanoparticle gel formulation (1:5 CS-SD). Conclusion: The anti-inflammatory effect of PA nanoparticles loaded gel on female guinea pig eyes was significantly superior to that of the micronized drug loaded gel ( P < 0.05).

show abstract

“…5,6 In addition, the diluted clinical formulation has only short-term physical stability (12–24 h) and tends to precipitate out from the aqueous media. 7…”

Section: Introductionmentioning

confidence: 99%

“…5,6 In addition, the diluted clinical formulation has only short-term physical stability (12-24 h) and tends to precipitate out from the aqueous media. 7 The limitations can be overcome by using drug delivery systems which are administration of a drug to achieve a therapeutic effect with safety and convenience to patients, and nanoparticles have been attracted much attention as potential carriers for drug delivery due to their unique and stable core-shell structure. [8][9][10] Various polymeric materials can be used to develop nanoparticle carriers.…”

Section: Introductionmentioning

confidence: 99%

Effective method of chitosan-coated alginate nanoparticles for target drug delivery applications

et al. 2016

View full text Add to dashboard Cite

In the present study, alginate nanoparticles were firstly prepared for paclitaxel (PTX) delivery with an average size of 200 ± 21 nm. To improve the stability and targeting effect, the chitosan (CS) and folate-chitosan (FA-CS) were introduced to form PTX-loaded CS/ALG NPs and FA-CS/ALG NPs by a new double emulsion cross-linking electrostatic attraction method. The optimization chitosan concentration was 0.5% obtained from the experiment results. The CS/ALG-PTX NPs and FA-CS/ALG-PTX NPs had the average particle size of 306.9 ± 12.9 nm and 283.6 ± 19.2 nm with the zeta potential of 31.1 ± 1.3 mV and -2.98 ± 0.7 mV, and had higher drug loading and entrapment efficiencies than ALG-PTX NPs. The in vitro drug release profile along with release kinetics and mechanism from PTX-loaded NPs were studied under two simulated physiological conditions. Further, the in vitro anti-cancer activity of nanoparticles and the cellular uptake of nanoparticles on HepG2 cells were investigated. The results demonstrated that alginate, CS/ALG and FA-CS/ALG can be used as nanoformulation drug carriers by our new method, and FA-CS/ALG was a promising vehicle for anticancer drug targeted delivery system.

show abstract

Bile acid conjugated chitosan oligosaccharide nanoparticles for paclitaxel carrier

Cited by 8 publications

References 26 publications

Design and Synthesis of Lactose, Galactose and Cholic Acid Related Dual Conjugated Chitosan Derivatives as Potential Anti Liver Cancer Drug Carriers

Design and Synthesis of Lactose, Galactose and Cholic Acid Related Dual Conjugated Chitosan Derivatives as Potential Anti Liver Cancer Drug Carriers

<p>Ocular anti-inflammatory activity of prednisolone acetate loaded chitosan-deoxycholate self-assembled nanoparticles</p>

Effective method of chitosan-coated alginate nanoparticles for target drug delivery applications

Contact Info

Product

Resources

About